Skip to main content

Table 1 Baseline characteristics

From: The impact of androgen deprivation therapy on the lipid profile in patients with prostate carcinoma

  Orchidectomy LHRH agonist p value
Number 29 40  
Age (years)* 70.4 ± 5.7 69.1 ± 5.9 0.39
BMI (kg/m2)* 22.8 ± 3.4 22.8 ± 3 0.71
Diabetes 15 20 1
Hypertension 14 17 0.82
Serum PSA (ng/ml)* 55.4 ± 50.2 50.1 ± 45.3 0.64
Locally advanced/Metastatic prostate cancer (as per EAU definitions) 14/15 18/22 0.81
Gleason score* 8.1 ± 1.1 8.2 ± 1.2 0.48
CAB 23 34 0.85
  1. BMI body mass index, CAB combined androgen blockade, EAU European Association of Urology
  2. *Data in mean ± SD